Vericel Corp (VCEL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Vericel Corp (VCEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012244
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell therapy products in the US: Carticel, an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement for the treatment of patients with deep-dermal. The company also develops MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treating advanced heart failure. It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. Vericel is headquartered in Cambridge, the US.

Vericel Corp (VCEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vericel Corp, Medical Devices Deals, 2011 to YTD 2017 10
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vericel Corp, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 12
Equity Offering 13
Vericel Raises USD19.6 Million in Public Offering of Shares 13
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Aastrom Biosciences Announces Public Offering Of US$20.3 Million 20
Acquisition 21
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 21
Vericel Corp – Key Competitors 22
Vericel Corp – Key Employees 23
Vericel Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 25
Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 27
May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 29
Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 31
Nov 07, 2016: Vericel Reports Third-Quarter 2016 Financial Results 33
Aug 08, 2016: Vericel Reports Second-Quarter 2016 Financial Results 35
May 10, 2016: Vericel Reports First-Quarter 2016 Financial Results 37
Mar 14, 2016: Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results 38
Corporate Communications 40
Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 40
Product News 41
09/07/2016: Vericel to Present Data at the American Heart Associations Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial 41
04/04/2016: Cell Therapy May Mend Damaged Hearts, Study Says 42
03/29/2016: Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions 43
03/28/2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy 44
Product Approvals 45
Feb 21, 2017: Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy 45
Clinical Trials 46
Nov 14, 2016: Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericels Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T 46
Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet 47
Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Vericel Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vericel Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Vericel Corp, Medical Devices Deals, 2011 to YTD 2017 10
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 12
Vericel Raises USD19.6 Million in Public Offering of Shares 13
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Aastrom Biosciences Announces Public Offering Of US$20.3 Million 20
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 21
Vericel Corp, Key Competitors 22
Vericel Corp, Key Employees 23
Vericel Corp, Other Locations 24
Vericel Corp, Subsidiaries 24

★海外企業調査レポート[Vericel Corp (VCEL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ricoh India Ltd:企業の戦略的SWOT分析
    Ricoh India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Monadelphous Group Ltd (MND):企業の財務・戦略的SWOT分析
    Monadelphous Group Ltd (MND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Samsung C&T Corporation:企業の戦略・SWOT・財務情報
    Samsung C&T Corporation - Strategy, SWOT and Corporate Finance Report Summary Samsung C&T Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Japan Wind Development Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Japan Wind Development Co Ltd (JWD) is a renewable energy company that operates and develops wind power generation plants. The company offers operation and maintenance, construction and development of wind power plants. It also develops green power system integration technology. JWD’s power …
  • Vestas Wind Systems AS (VWS)-エネルギー分野:企業M&A・提携分析
    Summary Vestas Wind Systems A/S (Vestas) is a renewable energy company that designs, manufactures, constructs, installs, and services wind turbines. The company partners with customers to monitor wind energy production and performance of the wind power plant throughout its lifetime. It offers soluti …
  • Copenhagen Airports AS:企業の戦略・SWOT・財務情報
    Copenhagen Airports AS - Strategy, SWOT and Corporate Finance Report Summary Copenhagen Airports AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CCP Technologies Ltd (CT1):医療機器:M&Aディール及び事業提携情報
    Summary CCP Technologies Ltd (CCP), formerly Agenix Ltd, is a technology company that offers business-to-business hardware and software solutions. The company develops Internet of Things’ solutions for management of computers, smart phones, sensors and diverse equipment. It offers business hardware …
  • Novozymes AS (NZYM B):企業の財務・戦略的SWOT分析
    Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Microgen plc (MCGN):企業の財務・戦略的SWOT分析
    Microgen plc (MCGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Industrial Alliance Insurance and Financial Services Inc.:企業の戦略・SWOT・財務情報
    Industrial Alliance Insurance and Financial Services Inc. - Strategy, SWOT and Corporate Finance Report Summary Industrial Alliance Insurance and Financial Services Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the co …
  • Kenon Holdings Ltd (KEN):企業の財務・戦略的SWOT分析
    Kenon Holdings Ltd (KEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Orbis Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Orbis Biosciences Inc (Orbis) is a developer of pharmaceutical products that offers optimizes oral and injectable products. The company provides preclnical pipeline indications for pathologies including cancer, bronchiolitis, Eczema, atopic dermatitis, nephrotic syndrome, HIV, asthma, bunine …
  • The Brink’s Company:企業の戦略・SWOT・財務情報
    The Brink's Company - Strategy, SWOT and Corporate Finance Report Summary The Brink's Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Boule Diagnostics AB (BOUL):医療機器:M&Aディール及び事業提携情報
    Summary Boule Diagnostics AB (Boule) is a medical device company that offers hematology diagnostic solutions. The company provides systems and consumer products for complete blood counts to non-institutional healthcare. It offers products such as blood cell counter and instruments, reagents, calibra …
  • PT Medco Energi Internasional Tbk (MEDC):電力:M&Aディール及び事業提携情報
    Summary PT Medco Energi Internasional Tbk (MedcoEnergi), a subsidiary of Encore Energy Pte. Ltd., is an integrated energy company. It explores for and develops oil and gas fields. The company provides energy related services such as power production, engineering procurement and construction (EPC), o …
  • John Wood Group Plc (WG.):企業の財務・戦略的SWOT分析
    John Wood Group Plc (WG.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ResApp Health Ltd (RAP):企業の製品パイプライン分析
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Coca-Cola HBC-Srbija d.o.o.:企業の戦略・SWOT・財務情報
    Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • The New York Times Company:企業の戦略・SWOT・財務分析
    The New York Times Company - Strategy, SWOT and Corporate Finance Report Summary The New York Times Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Forward Industries, Inc. (FORD):企業の財務・戦略的SWOT分析
    Forward Industries, Inc. (FORD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆